Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease

Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effect of LCIG on Advanced Parkinson’s Disease (APD) patients QoL. Secondarily, the imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Valldeoriola, Francesc, Catalán, María José, Escamilla-Sevilla, Francisco, Freire, Eric, Olivares, Jesús, Cubo, Esther, García, Diego Santos, Calopa, Matilde, Martínez-Martín, Pablo, Parra, Juan Carlos, Arroyo, Gloria, Arbelo, José Matías
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633325/
https://www.ncbi.nlm.nih.gov/pubmed/34848716
http://dx.doi.org/10.1038/s41531-021-00246-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633325/
https://www.ncbi.nlm.nih.gov/pubmed/34848716
http://dx.doi.org/10.1038/s41531-021-00246-y

Ejemplares similares